Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Dec. 6 in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected.

State-owned Shanghai Securities News reported significantly discounted prices for drugs in the program,

Read the full 429 word article

How to gain access

Continue reading with a
two-week free trial.